摘要
目的研究叉头框蛋白Q1（FOXQ1）在肝细胞癌（HCC）组织中的表达情况,探讨其对手术切除后行经肝动脉化疗栓塞术预后的影响,分析FOXQ1在评估肝癌疗效中的价值。方法收集2004年1月-2007年12月南通大学附属肿瘤医院收治的HCC患者120例。采用免疫组化分析FOXQ1在HCC组织中的表达情况,与患者临床特征进行比较。计数资料组间比较采用χ2检验;利用Kaplan-Meier曲线和log-rank分析患者术后的无瘤生存率（DFS）;采用Cox比例风险回归模型进行单因素和多因素回归分析。结果免疫组化结果显示,FOXQ1在癌组织中呈深褐色,主要表达于肿瘤细胞质和细胞核中。单因素回归分析结果显示患者术后5年的DFS受肝脏TNM分期[风险比（HR）=0.347,95%可信区间（95%CI）：0.210-0.573,P〈0.001]、肝内肿瘤个数（HR=0.294,95%CI：0.176-0.490,P〈0.001）、HBV感染情况（HR=0.395,95%CI：0.222-0.704,P=0.002）、AFP表达水平（HR=0.348,95%CI：0.207-0.586,P〈0.001）、是否肝硬化（HR=0.414,95%CI：0.244-0.702,P=0.001）、FOXQ1高表达（HR=1.968,95%CI：1.171-3.308,P=0.011）等因素影响;多因素回归分析发现肝癌患者术后5年的DFS与TNM分期（HR=0.466,95%CI：0.248-0.874,P=0.017）、肝内肿瘤个数（HR=0.427,95%CI：0.216-0.844,P=0.014）、FOXQ1高表达（HR=2.896,95%CI：1.628-5.152,P〈0.001）有关,FOXQ1高表达的患者治疗后无瘤生存时间小于FOXQ1低表达患者（18个月vs 26个月,χ2=5.006,P=0.025）。结论 FOXQ1可作为判断肝癌患者预后的生物标志物,用于评价肝癌治疗效果。
Objective To investigate the expression of Forkhead box Q1（ FOXQ1） in the tissue of hepatocellular carcinoma（ HCC）,its influence on the prognosis of surgical resection combined with transarterial chemoembolization（ TACE）,and the value of FOXQ1 in evaluating the treatment outcome of HCC. Methods A total of 120 HCC patients who were admitted to The Affiliated Tumor Hospital of Nantong University from January 2004 to December 2007 were enrolled. Immunohistochemistry was used to measure the expression of FOXQ1 in HCC tissue,which was compared with patients＇ clinical features. The chi- square test was used for comparison of categorical data between groups,the Kaplan- Meier curve and log- rank test were used to analyze patients＇ disease- free survival（ DFS） rates after surgery,and the Cox proportional hazards regression model was used for univariate and multivariate regression analyses. Results The results of immunohistochemistry showed that FOXQ1 had a dark- brown color in HCC tissue and was mainly expressed in tumor cytoplasm and nucleus. The univariate regression analysis showed that patients＇ DFS was affected by TNM stage（ HR = 0. 347,95% CI： 0. 210- 0. 573,P〈0. 001）,the number of tumors in the liver（ HR = 0. 294,95% CI： 0. 176- 0. 490,P〈0. 001）,HBV infection（ HR = 0. 395,95% CI： 0. 222-0. 704,P = 0. 002）,alpha- fetoprotein expression（ HR = 0. 348,95% CI： 0. 207- 0. 586,P〈0. 001）,presence or absence of liver cirrhosis（ HR = 0. 414,95% CI： 0. 244- 0. 702,P = 0. 001）,and high FOXQ1 expression level（ HR = 1. 968,95% CI： 1. 171- 3. 308,P = 0. 011）. Multivariate regression analysis showed that the patents＇ DFS was associated with TNM stage（ HR = 0. 466,95% CI： 0. 248-0. 874,P = 0. 017）,the number of tumors in the liver（ HR = 0. 427,95% CI： 0. 216- 0. 844,P = 0. 014）,and high FOXQ1 expression level（ HR = 2. 896,95% CI： 1. 628- 5. 152,P〈0. 001）. The patients with a high FOXQ1 expression level had a shorter DFS than those with a low FOXQ1 expression level（ 18 months vs 26 months,χ2= 5. 006,P = 0. 025）. Conclusion FOXQ1 can be used as a biomarker to evaluate the prognosis of HCC patients and the treatment outcome of HCC.
出处
《临床肝胆病杂志》
CAS
2016年第11期2126-2129,共4页
Journal of Clinical Hepatology
基金
江苏省南通市卫生青年基金资助项目(WQ2015047)
江苏省南通市科技计划指导性项目(YYZ15006)
关键词
癌
肝细胞
叉头转录因子类
化学栓塞
治疗性
carcinoma
hepatocellular
forkhead transcription factors
chemoembolization
therapeutic
